Dominic D'Agostino

There's some work done with MCT.

Sam Henderson published in 2008 when the molecule was AC1202.

But if you look at the patent, it was just caprylic triglyceride.

And actually improved mini-mental status exam.

And Dr. Mary Newport saw that and gave her husband coconut oil and MCT oil.

And he improved.

And a case report with Dr. Veach being one of the co-authors on that was published.

just a ketogenic intervention.

And they followed, that was the longest case report for years, followed his progression and stabilization.

He ended up succumbing to the disease, but she got many more years with him through ketogenic intervention.

So I think we have to think about putting together a comprehensive metabolic-based formula.

And Dale Bredesen has been spearheading some things and looking at more of a comprehensive approach.

Dr. Stephen Cunane has been working on MCTs and other ketogenic agents for Alzheimer's.

Also did a dual PET scan where you do a glucose ketone PET scan and showed and published that as we age, our capacity to use glucose decreases over time, but that does not happen with ketones.

Our brain's ability to use ketones over time is preserved.

So that's an important distinction and a good foundational framework for the rationale for doing ketone metabolic therapy.

But I think you'll probably have more benefit by thinking about it as a comprehensive metabolic therapy where you can target different things.

And I think there's a number of different molecules like alpha-GPC, but no one does anything with formulations.

they're pretty much always doing.

A funding agency is not going to fund it.